Claims And Counterclaims Abound In Highly Competitive Breast Cancer Genomics Market
Executive Summary
Companies active in the breast cancer genomics market are waging a war of words and data to push their respective tests forward. With an expanding volume of data showing that genomic testing can save many patients from unnecessary chemotherapy treatment, and positive recommendations issued in major clinical practice guidelines, there is a compelling argument – from both a quality of care and overall economic standpoint – for physicians to use these tests, and strong growth is anticipated in this space going forward.
You may also be interested in...
Molecular Diagnostics Moves Into Prostate Cancer
While the PSA test is still widely recognized as a valuable prostate cancer screening tool, its dismal accuracy record has created an acute need for more effective and informative alternatives, and the field of molecular diagnostics, based on gene-based biomarkers, is leading the charge.
The Evolving World Of Breast Cancer Management
The device industry is playing a pivotal role in the evolution toward a more personalized approach to breast cancer management, with ongoing advances in minimally invasive treatment systems, tumor characterization and breast imaging technologies adding to the momentum. In the years ahead, as the breast cancer toolbox expands, the watchword will be “choice,” with physicians and patients offered more treatment options, targeted to their specific needs and desires, than ever before.